

ASX ANNOUNCEMENT

Change in substantial shareholdings

For Immediate Release: 1 August 2018

Sydney, Australia – Simavita Limited (**Simavita** or the **Company**) (ASX: SVA) refers to the Appendix 3B released on 1 August 2018 for the issue of 36,045,208 Chess Depositary Interests (**CDIs**).

The issue of CDIs was due to the conversion of Convertible Notes, including interest, approved at the 2017 Annual General Meeting. As a result of the conversion there has been a change to substantial shareholding of several holders as detailed below:

| Holder | Previous Announcement | This Announcement | % change |
|------------------------------|--------------------------|-------------------|----------|
| Dussman Group | Dated 29/5/2017 | 102,019,031 | 3.69% |
| | 78,160,131 CDIs (25.80%) | (29.49%) | |
| Jolimont Lodge Pty Ltd atf | Dated 15/6/2017 | 28,251,991 CDIs | 0.78% |
| Powell Superannuation Fund | 22,912,265 CDIs (7.39%) | (8.17%) | |
| Robert Hutchison and Mary | Dated 15/6/2017 | 18,360,286 CDIs | -0.23% |
| Ann McKenzie atf Inspiration | 17,025,354 CDIs (5.54%) | (5.31%) | |
| Superannuation Fund | | | |
| Parmelia Pty Ltd atf Reilly | Dated 12/5/2017 | 35,511,650 | 0.77% |
| Family Super Fund a/c | 27,500,000 CDIs (9.50% | (10.27%) | |

For further information, please check our website (<u>www.simavita.com</u>) or contact:

Ms Peta Jurd

E: <u>pjurd@simavita.com</u>
T: +61 2 8405 6361

About Simavita

Simavita (ASX: SVA) develops and markets advanced systems associated with smart, wearable and disposable sensors for the global diaper manufacturing industry and also for the aged and disabled care markets. This industry currently generates approximately USD 21bn in annual revenues.

Simavita offers an extremely low cost sensor platform technology for everyday use in all adult and infant diapers. AlertPLUS™ is incorporated into the diaper manufacturing process and connects to your smart device via an App. The platform is ready for partnering with major international diaper manufacturers.

Simavita's technology portfolio also includes AssessPLUS™, an easy to use tablet based product for the assessment of incontinence which delivers a personalised, evidence base incontinence care plan.

With the support of our shareholders, customers and employees, Simavita is absolutely committed to the business at hand; creating a commercially successful and growing corporation. www.simavita.com